Organovo relocates to larger premises
Includes cleanroom to protect functional human tissues created by NovoGen MMX 3D bioprinting process
Organovo Holdings, a US-based biotechnology company focused on delivering three-dimensional (3D) bioprinting technology, has moved its headquarters to a 15,500ft2 facility in San Diego, California.
The facility consists of mixed lab and office space with cleanroom space nearly four times larger than previously. Cleanroom facilities are required for protection of the functional human tissues created by Organovo's NovoGen MMX 3D bioprinting process.
In the expanded facility, Organovo will continue to focus on bioprinting to create an array of functional 3D tissues that can be used in in vivo biology for human disease research, drug discovery and development, toxicology testing and, eventually, as therapies.
Keith Murphy, chairman and chief executive of Organovo, said: ‘We now have the space to expand our expertise into additional areas of research and development and to expand our bioprinting capacity with up to four NovoGen MMX Bioprinters in regular operation.
‘The new facility provides essential resources for Organovo to advance the development of new bioprinter technologies, 3D drug discovery models, and 3D cellular assays and research to create functional human tissues for surgical transplant.’
